Streetbeat News

COCH

Envoy Medical, Inc.

https://www.envoymedical.com

Industry

Medical - Devices

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices; and Acclaim cochlear implants. Envoy Medical Corporation was formerly known as St. Croix Medical, Inc. and changed its name to Envoy Medical Corporation in December 2004. The company was founded in 1995 and is based in White Bear Lake, Minnesota.

Open

1.38

Mkt cap

30M

Volume

7.3K

High

1.51

P/E Ratio

-1.12

52-wk high

7.20

Low

1.38

Div yield

N/A

52-wk low

1.21

Brookline Capital has initiated coverage on Envoy Medical with a Buy rating and set a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:07 pm

Envoy Medical has been awarded a new patent for a recharge system used with implantable batteries, enhancing their portfolio in developing fully implanted hearing devices.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:08 pm

Insider buying activity has been observed in three penny stocks: 60 Degrees Pharmaceuticals, Envoy Medical, and Hyliion Holdings. This insider activity may indicate confidence in the companies' prospects. Notably, Hyliion Holdings secured a $15 million contract with the Office of Naval Research.

Portfolio Pulse from Avi Kapoor

September 12, 2024 | 11:19 am

Ascendiant Capital has maintained a Buy rating on Envoy Medical and raised the price target from $8.5 to $8.75.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 9:38 am

Envoy Medical, a company focused on fully implanted hearing devices, has secured a $10 million lending facility, drawing $5 million initially. This funding, provided by major shareholder Glen Taylor, supports the company's growth and milestone achievements.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:07 pm

Envoy Medical shares are trading higher following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:24 pm

Envoy Medical (NASDAQ:COCH) reported Q2 EPS of $(0.27), missing the $(0.25) estimate, and sales of $68.00K, missing the $82.50K estimate. Despite the misses, EPS improved by 79.39% and sales increased by 7.94% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:45 pm

Envoy Medical has been added to the Russell Microcap Index, which could increase its visibility and attract more investors.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:05 pm

Envoy Medical shares are trading higher after Ascendiant Capital initiated coverage with a Buy rating and announced a price target of $8.50.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 2:25 pm

Ascendiant Capital has initiated coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and set a price target of $8.5.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 9:41 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.